News
With U.S. stocks booming, North American wealthy led the way globally. And the top 1% of wealthy globally—the so-called ...
Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...
At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...
Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...
US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...
Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...
Helgi Kormaksson Joins CTS Executive Team SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / CTS is excited to announce that Helgi Kormaksson has joined the company as Chief Design Officer. Helgi ...
Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...
SINGAPORE—China is racing toward economic self-sufficiency by weaning itself off American technology. But it has made a ...
Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model ...
14h
MedPage Today on MSNWhy Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years LaterWhen journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results